Jilin Pharmaceutical USA, Inc.
Jilin Pharmaceutical USA, Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States and operates extensively across various regions. Founded in 1999, the company has established itself as a leader in the development and manufacturing of high-quality pharmaceutical products, particularly in the fields of generic medications and active pharmaceutical ingredients (APIs). Jilin Pharmaceutical is renowned for its commitment to innovation and quality, offering a diverse portfolio that includes both prescription and over-the-counter medications. The company’s unique approach to research and development has positioned it favourably in a competitive market, earning recognition for its rigorous quality control standards and compliance with international regulations. With a strong market presence, Jilin Pharmaceutical USA continues to contribute significantly to the healthcare sector, ensuring access to essential medicines for patients worldwide.
DitchCarbon Score
How does Jilin Pharmaceutical USA, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Jilin Pharmaceutical USA, Inc.'s score of 23 is lower than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Jilin Pharmaceutical USA, Inc.'s reported carbon emissions
Jilin Pharmaceutical USA, Inc. currently does not have available carbon emissions data for the most recent year, nor are there specific reduction targets or climate pledges outlined in their initiatives. Without concrete figures or commitments, it is challenging to assess their carbon footprint or climate strategy. However, the company may still be engaged in industry-standard practices aimed at reducing environmental impact, although specific details are not provided. As the pharmaceutical industry increasingly focuses on sustainability, Jilin Pharmaceutical USA, Inc. may consider establishing measurable targets and reporting frameworks to align with global climate commitments in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Jilin Pharmaceutical USA, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
